Sign In
Buy MLYS
$25.61
+0.240 (+0.95%)
At Close: Jun 23, 2026
Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference
08:00am, Tuesday, 05'th May 2026
RADNOR, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities
Mineralys Therapeutics to Announce First Quarter 2026 Financial Results and Host Conference Call on Wednesday, May 6, 2026
04:05pm, Wednesday, 29'th Apr 2026
RADNOR, Pa., April 29, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbiditie
David Malcom Rodman Sells 2,170 Shares of Mineralys Therapeutics (NASDAQ:MLYS) Stock
04:28am, Wednesday, 15'th Apr 2026
Mineralys Therapeutics, Inc. (NASDAQ: MLYS - Get Free Report) insider David Malcom Rodman sold 2,170 shares of the stock in a transaction dated Thursday, April 9th. The stock was sold at an average pr
Mineralys Therapeutics' CEO Sold Shares Worth $1.97 Million. Should Investors Avoid the Stock?
11:10am, Tuesday, 07'th Apr 2026
CEO Jon Congleton sold 75,000 shares for a total transaction value of ~$1.97 million on April 2, 2026. The sale represented 9.61% of direct holdings prior to the transaction, reducing direct ownership
Mineralys Therapeutics (NASDAQ:MLYS) CEO Jon Congleton Sells 75,000 Shares
05:17am, Friday, 03'rd Apr 2026
Mineralys Therapeutics, Inc. (NASDAQ: MLYS - Get Free Report) CEO Jon Congleton sold 75,000 shares of the company's stock in a transaction on Tuesday, March 31st. The shares were sold at an average pr
Mineralys Therapeutics Appoints Jeffrey A. Munsie as Chief Legal Officer
08:00am, Tuesday, 24'th Mar 2026
RADNOR, Pa., March 24, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbiditie
Mineralys Therapeutics, Inc. (MLYS) Q4 2025 Earnings Call Transcript
07:32pm, Thursday, 12'th Mar 2026
Mineralys Therapeutics, Inc. (MLYS) Q4 2025 Earnings Call Transcript
Mineralys Therapeutics Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update
04:05pm, Thursday, 12'th Mar 2026
– Announced FDA acceptance of NDA for lorundrostat in adults with hypertension; assigned PDUFA target date of December 22, 2026 – – Conference call today at 4:30 p.m. ET – RADNOR, Pa.
Capital International Investors Sells 505,624 Shares of Mineralys Therapeutics, Inc. $MLYS
04:44am, Thursday, 12'th Mar 2026
Capital International Investors decreased its holdings in Mineralys Therapeutics, Inc. (NASDAQ: MLYS) by 17.4% during the third quarter, according to the company in its most recent disclosure with the
Barclays PLC Has $24.79 Million Stock Holdings in Mineralys Therapeutics, Inc. $MLYS
03:59am, Thursday, 12'th Mar 2026
Barclays PLC boosted its holdings in shares of Mineralys Therapeutics, Inc. (NASDAQ: MLYS) by 354.4% during the third quarter, according to its most recent 13F filing with the Securities and Exchange
Mineralys Stock Rises as FDA Accepts NDA for Hypertension Drug
12:35pm, Wednesday, 11'th Mar 2026
MLYS shares rise after the FDA accepts NDA for lorundrostat to treat hypertension. A decision from the regulatory body is due on Dec. 22, 2026.
– The FDA assigned a PDUFA target action date of December 22, 2026 – – The NDA is based on positive data from a successful clinical program demonstrating favorable safety and blood pressure redu
RADNOR, Pa., March 09, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbiditie
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Thursday, 26'th Feb 2026
RADNOR, Pa., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and relate
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Given Consensus Rating of “Moderate Buy” by Analysts
03:29am, Thursday, 19'th Feb 2026
Mineralys Therapeutics, Inc. (NASDAQ: MLYS - Get Free Report) has received an average recommendation of "Moderate Buy" from the eight ratings firms that are currently covering the firm, Marketbeat Rat
